个人中心 - 老虎社区

Julyvictor

IP属地：未知

帖子 · 10帖子 · 10
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- JulyvictorJulyvictor
  ·2021-05-05
  Will this affect virtual coins
  非常抱歉，此主贴已删除
  719 评论
  点赞
  分享
  举报
- JulyvictorJulyvictor
  ·2021-05-05
  Comment done
  3 Stocks I Fully Expect to Double or More Within the Next 5 Years
  DermTechDermTech(NASDAQ:DMTK)might scare off some investors because of its volatility. Thehealthcare
  3 Stocks I Fully Expect to Double or More Within the Next 5 Years
  380 2
  2
  分享
  举报
- JulyvictorJulyvictor
  ·2021-05-05
  Check
  Here's How Warren Buffett Explained Berkshire Hathaway's Bank Selloff
  Berkshire Hathaway's(NYSE:BRK.A)(NYSE:BRK.B)annual shareholder meeting and its marathon question-and
  Here's How Warren Buffett Explained Berkshire Hathaway's Bank Selloff
  374 2
  2
  分享
  举报
- JulyvictorJulyvictor
  ·2021-05-05
  Why not take financial firms?
  非常抱歉，此主贴已删除
  575 1
  3
  分享
  举报
- JulyvictorJulyvictor
  ·2021-05-05
  Not financial institution?
  非常抱歉，此主贴已删除
  413 评论
  点赞
  分享
  举报
- JulyvictorJulyvictor
  ·2021-05-02
  Medical device maker
  444 评论
  点赞
  分享
  举报
- JulyvictorJulyvictor
  ·2021-04-30
  Interesting
  3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners
  David Gardner, a co-founder of The Motley Fool, often says that "winners win." And he's exactly righ
  3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners
  317 评论
  点赞
  分享
  举报
- JulyvictorJulyvictor
  ·2021-04-30
  Good info
  3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners
  David Gardner, a co-founder of The Motley Fool, often says that "winners win." And he's exactly righ
  3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners
  325 1
  点赞
  分享
  举报
- JulyvictorJulyvictor
  ·2021-04-30
  Interesting and bravo
  非常抱歉，此主贴已删除
  373 评论
  1
  分享
  举报
- JulyvictorJulyvictor
  ·2021-04-17
  Is Tesla worth? Hope so
  440 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576543142815799","uuid":"3576543142815799","gmtCreate":1613449290109,"gmtModify":1618624531489,"name":"Julyvictor","pinyin":"julyvictor","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":7,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.22","exceedPercentage":"60.69%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":102107230,"gmtCreate":1620181683120,"gmtModify":1634207165735,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Will this affect virtual coins","listText":"Will this affect virtual coins","text":"Will this affect virtual coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102107230","repostId":"2133549480","repostType":4,"isVote":1,"tweetType":1,"viewCount":719,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102107368,"gmtCreate":1620181636154,"gmtModify":1634207166104,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Comment done","listText":"Comment done","text":"Comment done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/102107368","repostId":"1183454115","repostType":4,"repost":{"id":"1183454115","kind":"news","pubTimestamp":1620180427,"share":"https://www.laohu8.com/m/news/1183454115?lang=&edition=full","pubTime":"2021-05-05 10:07","market":"us","language":"en","title":"3 Stocks I Fully Expect to Double or More Within the Next 5 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=1183454115","media":"The motley fool","summary":"DermTechDermTech(NASDAQ:DMTK)might scare off some investors because of its volatility. Thehealthcare","content":"<p>DermTech</p><p><b>DermTech</b>(NASDAQ:DMTK)might scare off some investors because of its volatility. Thehealthcare stocksoared 145% year to date by late February only to give up much of those gains. In my view, it's best to ignore the short-term volatility and focus on DermTech's long-term prospects.</p><p>The company markets two genomics tests for detecting melanoma called Pigmented Lesion Assay (PLA) and PLAPlus. With these tests, an adhesive patch is placed over a suspect area of skin. The patch is then removed and sent to DermTech's lab for genetic analysis.</p><p>DermTech's tests are 17 times less likely to miss a melanoma diagnosis than the current method of obtaining a tissue biopsy and sending it to a lab for histological analysis. The cost of the PLA skin genomics test is also nearly 25% less expensive than the current approach.</p><p>It's still in the really early innings for DermTech. Not every insurer covers the company's tests yet. Many dermatologists aren't familiar with the tests. DermTech is also still developing similar tests for other skin cancers.</p><p>But I predict significantly increased payer coverage and dermatologist adoption as well as success for the company in launching new products over the next few years. With DermTech's market cap currently at around $1.2 billion, I think this stock has a great chance to double and perhaps deliver a much higher return.</p><p>Etsy</p><p>The Motley Foolrecently revealed 20 of its highest-conviction stock and fund picksthat are in a great position to make investors money over the next five years.&nbsp;<b>Etsy</b>(NASDAQ:ETSY)ranked as the second smallest stock on the list with its market cap close to $25 billion. I also have a really high conviction about Etsy's potential.</p><p>There's no doubt in my mind that online shopping will grow over the next several years. I think that Etsy will grow even faster than the overall e-commerce market. That was definitely the case in 2020, with Etsy's gross merchandise sales soaring 2.5 times faster than the U.S. Census Bureau's e-commerce industry benchmark.</p><p>In my opinion, there's one main reason this trend is likely to continue: Etsy's uniqueness. The company's platform features many one-of-a-kind handcrafted products that you simply can't find anywhere else. This differentiation has helped make Etsy the fourth-largest e-commerce site in the U.S. based on monthly visits.</p><p>Etsy could realistically double by focusing only on the $100 billion market for what it calls \"special\" products. However, the company is also targeting a broader e-commerce market that's much bigger. I look for Etsy to continue gaining market share and provide investors who buy and hold the stock huge gains over the next few years.</p><p>Gores Holdings VI</p><p>I'm not usually a fan of special purpose acquisition company (SPAC) stocks. However,&nbsp;<b>Gores Holdings VI</b>(NASDAQ:GHVI)is an exception. I really like the prospects for the company that this SPAC plans to soon merge with -- Matterport.</p><p>Matterport stands as the leader in creating 3D \"digital twins\" of buildings. It has created the world's biggest library of these 3D models with more than 10 billion square feet of space digitized. Matterport generates revenue primarily through a software-as-a-service model.</p><p>The company estimates its total addressable market is close to $240 billion. The opportunities for its technology include facilities management, insurance pricing, interior design, and real estate marketing.</p><p>Gores Holdings VI and Matterport expect the combined company will have a market cap of around $2.9 billion after their merger closes. That might seem like a steep valuation considering that Matterport made only $86 million in sales last year. However, the company thinks it could generate nearly six times that amount by 2025. If it even comes close to that goal, this SPAC stock should easily double or more within the next five years.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks I Fully Expect to Double or More Within the Next 5 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks I Fully Expect to Double or More Within the Next 5 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/04/3-stocks-i-fully-expect-to-double-or-more-within-t/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DermTechDermTech(NASDAQ:DMTK)might scare off some investors because of its volatility. Thehealthcare stocksoared 145% year to date by late February only to give up much of those gains. In my view, it'...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/04/3-stocks-i-fully-expect-to-double-or-more-within-t/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETSY":"Etsy, Inc."},"source_url":"https://www.fool.com/investing/2021/05/04/3-stocks-i-fully-expect-to-double-or-more-within-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183454115","content_text":"DermTechDermTech(NASDAQ:DMTK)might scare off some investors because of its volatility. Thehealthcare stocksoared 145% year to date by late February only to give up much of those gains. In my view, it's best to ignore the short-term volatility and focus on DermTech's long-term prospects.The company markets two genomics tests for detecting melanoma called Pigmented Lesion Assay (PLA) and PLAPlus. With these tests, an adhesive patch is placed over a suspect area of skin. The patch is then removed and sent to DermTech's lab for genetic analysis.DermTech's tests are 17 times less likely to miss a melanoma diagnosis than the current method of obtaining a tissue biopsy and sending it to a lab for histological analysis. The cost of the PLA skin genomics test is also nearly 25% less expensive than the current approach.It's still in the really early innings for DermTech. Not every insurer covers the company's tests yet. Many dermatologists aren't familiar with the tests. DermTech is also still developing similar tests for other skin cancers.But I predict significantly increased payer coverage and dermatologist adoption as well as success for the company in launching new products over the next few years. With DermTech's market cap currently at around $1.2 billion, I think this stock has a great chance to double and perhaps deliver a much higher return.EtsyThe Motley Foolrecently revealed 20 of its highest-conviction stock and fund picksthat are in a great position to make investors money over the next five years. Etsy(NASDAQ:ETSY)ranked as the second smallest stock on the list with its market cap close to $25 billion. I also have a really high conviction about Etsy's potential.There's no doubt in my mind that online shopping will grow over the next several years. I think that Etsy will grow even faster than the overall e-commerce market. That was definitely the case in 2020, with Etsy's gross merchandise sales soaring 2.5 times faster than the U.S. Census Bureau's e-commerce industry benchmark.In my opinion, there's one main reason this trend is likely to continue: Etsy's uniqueness. The company's platform features many one-of-a-kind handcrafted products that you simply can't find anywhere else. This differentiation has helped make Etsy the fourth-largest e-commerce site in the U.S. based on monthly visits.Etsy could realistically double by focusing only on the $100 billion market for what it calls \"special\" products. However, the company is also targeting a broader e-commerce market that's much bigger. I look for Etsy to continue gaining market share and provide investors who buy and hold the stock huge gains over the next few years.Gores Holdings VII'm not usually a fan of special purpose acquisition company (SPAC) stocks. However, Gores Holdings VI(NASDAQ:GHVI)is an exception. I really like the prospects for the company that this SPAC plans to soon merge with -- Matterport.Matterport stands as the leader in creating 3D \"digital twins\" of buildings. It has created the world's biggest library of these 3D models with more than 10 billion square feet of space digitized. Matterport generates revenue primarily through a software-as-a-service model.The company estimates its total addressable market is close to $240 billion. The opportunities for its technology include facilities management, insurance pricing, interior design, and real estate marketing.Gores Holdings VI and Matterport expect the combined company will have a market cap of around $2.9 billion after their merger closes. That might seem like a steep valuation considering that Matterport made only $86 million in sales last year. However, the company thinks it could generate nearly six times that amount by 2025. If it even comes close to that goal, this SPAC stock should easily double or more within the next five years.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102104645,"gmtCreate":1620181592987,"gmtModify":1634207166350,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Check&nbsp;","listText":"Check&nbsp;","text":"Check","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/102104645","repostId":"1132504423","repostType":4,"repost":{"id":"1132504423","kind":"news","pubTimestamp":1620180873,"share":"https://www.laohu8.com/m/news/1132504423?lang=&edition=full","pubTime":"2021-05-05 10:14","market":"us","language":"en","title":"Here's How Warren Buffett Explained Berkshire Hathaway's Bank Selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=1132504423","media":"The motley fool","summary":"Berkshire Hathaway's(NYSE:BRK.A)(NYSE:BRK.B)annual shareholder meeting and its marathon question-and","content":"<p><b>Berkshire Hathaway</b>'s(NYSE:BRK.A)(NYSE:BRK.B)annual shareholder meeting and its marathon question-and-answer session have once again come and gone, offering investors another glimpse into the extraordinary mind of legendary investor Warren Buffett. Some of the questions that came up in Saturday's livestream dealt with moves Berkshire made during the early stages of the pandemic last year -- including what led the company to exit most of its banking positions while loading up on<b>Bank of America</b>(NYSE:BAC). After months of speculation, Buffett gave a little bit of insight into what drove his decision making.</p>\n<p>Too much exposure</p>\n<p>Prior to the pandemic, Berkshire owned a slate of bank stocks, and Buffett seemed to have a bullish stance toward the sector. However, as stay-at-home orders and economic shutdowns spread across the country and banks braced for heavy loan losses, Buffett seemed to do a 180 and exited many of his holdings.</p>\n<p>Berkshire eliminated its stake in investment bank<b>Goldman Sachs</b>&nbsp;and eventually<b>JPMorgan Chase</b>, America's largest bank by assets. Berkshire also sold its position in regional banks like<b>PNC Financial Services Group</b>&nbsp;and<b>M&amp;T Bank</b>. And Buffett appears to be looking for an exit on former favorite<b>Wells Fargo</b>, selling shares gradually for the past several quarters.</p>\n<p>While all of this was going on, Buffett and Berkshire pumped more than $2 billion of stock into Bank of America and increased the company's stake to 11.9% of outstanding shares, a move that required special regulatory approval.</p>\n<p><img src=\"https://static.tigerbbs.com/c2da7d6438277757a73f9e626ebc6fc2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>While we don't yet know what moves Buffett has made in 2021, he doesn't appear to have done much, since the cost basis of Berkshire's bank, insurance, and finance stocks after the first quarter was just slightly higher than it was at the end of 2020.</p>\n<p>During the Q&amp;A part of Berkshire's shareholder meeting, Buffett was asked why he had sold most of his bank stocks last year.</p>\n<p>\"I like banks generally, I just didn't like the proportion we had compared to the possible risk if we got the bad results that so far we haven't gotten,\" Buffett said. \"We overall didn't want as much in banks as we had.\"</p>\n<p>The Oracle of Omaha added: \"The banking business is way better than it was in the United States 10 or 15 years ago. The banking business around the world -- in various places -- might worry me. But our banks are in far, far better shape than 10 or 15 years ago. But when things froze for a short period of time, the biggest thing the banks had going for them was that the Federal Reserve was behind them, and the Federal Reserve is not behind Berkshire. It's up to us take care of ourselves.\"</p>\n<p>What to make of this</p>\n<p>Buffett is one of the greatest investing minds of all time, if not No. 1, so it's important to realize that it will be difficult for us to see these moves exactly as he does. And I can certainly appreciate his remark about having too much exposure. Keep in mind, Buffett is managing an equities portfolio of hundreds of billions of dollars, so a few percentage points one way or the other is huge. He needs to think about safety much more than your standard responsible investor (Buffett sometimes refers to himself as Berkshire's \"chief risk officer,\" and he did so again on Saturday). But it really is difficult for me to understand all these moves.</p>\n<p>Goldman Sachs is not very loan-heavy, so it didn't really face the same degree of risk as other large banks like Bank of America and JPMorgan Chase. Investment banks also tend to do better in periods of volatility, and Goldman is working to build up its consumerbankand asset and wealth management divisions to generate steadier revenues. Goldman's stock is nearly 40% higher than it was prior to the pandemic, and many thinkit's still trading cheap.</p>\n<p>Buffett's decision to load up on Bank of America and dump JPMorgan as an even bigger mystery to me. JPMorgan not only has a more diversified business, but its earnings power is greater, as well. The bank is also extremely safe. Its reserves for loan losses peaked at $34 billion during 2020, but the bank was prepared for scenarios where its reserves would have peaked at $52 billion. JPMorgan also engineered its way through the Great Recession better than any of the largest banks in America. Buffett officially eliminated Berkshire's stake in JPMorgan in the fourth quarter of the year. Meanwhile, the stock is up nearly 21% year to date at Tuesday's prices, and Buffett likely missed out on even more appreciation, considering he sold the bulk of his JPMorgan position in the third quarter of 2020.</p>\n<p>Hindsight is, of course, 20/20, but the numbers are also the numbers, and Buffett missed out on huge gains on his former bank holdings that could just be getting started. Banks are potentially poised for a strong multiyear run, with earnings expected to jump in a rising-rate environment. Buffett did say Saturday that he is concerned about \"very substantial inflation,\" so maybe he thinks too much inflation may kill loan demand, or that rising rates might reveal bad credit quality. However, cyclical stocks like banks and financials tend to perform better during inflation than high-growth tech stocks, which Berkshire has recently made abigger part of its portfoliothan financials.</p>\n<p>Is Buffett done with banking?</p>\n<p>Buffett has not abandoned the sector altogether. Bank of America is still Berkshire's second-largest holding behind<b>Apple</b>. Berkshire also still has large positions in<b>American Express</b>,&nbsp;<b>U.S. Bancorp</b>, and<b>Bank of New York Mellon</b>. Buffett also may not be pulling all the strings here -- he's ceded a lot of Berkshire's investing authority to others who may be making the decisions. It has long been known that two of Buffett's lieutenants, Todd Combs and Ted Weschler, are much more involved in Berkshire's portfolio decisions now. In addition, Berkshire recently confirmed that Berkshire's Vice Chairman Greg Abel isexpected to succeed Buffettas CEO when he eventually steps aside.</p>\n<p>But with all that has recently happened, it does seem like it could be a while until we see Berkshire buy traditional bank stocks again.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's How Warren Buffett Explained Berkshire Hathaway's Bank Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's How Warren Buffett Explained Berkshire Hathaway's Bank Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-05 10:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/04/heres-how-warren-buffett-explained-berkshire-hatha/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway's(NYSE:BRK.A)(NYSE:BRK.B)annual shareholder meeting and its marathon question-and-answer session have once again come and gone, offering investors another glimpse into the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/04/heres-how-warren-buffett-explained-berkshire-hatha/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BRK.A":"伯克希尔"},"source_url":"https://www.fool.com/investing/2021/05/04/heres-how-warren-buffett-explained-berkshire-hatha/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132504423","content_text":"Berkshire Hathaway's(NYSE:BRK.A)(NYSE:BRK.B)annual shareholder meeting and its marathon question-and-answer session have once again come and gone, offering investors another glimpse into the extraordinary mind of legendary investor Warren Buffett. Some of the questions that came up in Saturday's livestream dealt with moves Berkshire made during the early stages of the pandemic last year -- including what led the company to exit most of its banking positions while loading up onBank of America(NYSE:BAC). After months of speculation, Buffett gave a little bit of insight into what drove his decision making.\nToo much exposure\nPrior to the pandemic, Berkshire owned a slate of bank stocks, and Buffett seemed to have a bullish stance toward the sector. However, as stay-at-home orders and economic shutdowns spread across the country and banks braced for heavy loan losses, Buffett seemed to do a 180 and exited many of his holdings.\nBerkshire eliminated its stake in investment bankGoldman Sachs and eventuallyJPMorgan Chase, America's largest bank by assets. Berkshire also sold its position in regional banks likePNC Financial Services Group andM&T Bank. And Buffett appears to be looking for an exit on former favoriteWells Fargo, selling shares gradually for the past several quarters.\nWhile all of this was going on, Buffett and Berkshire pumped more than $2 billion of stock into Bank of America and increased the company's stake to 11.9% of outstanding shares, a move that required special regulatory approval.\n\nIMAGE SOURCE: GETTY IMAGES.\nWhile we don't yet know what moves Buffett has made in 2021, he doesn't appear to have done much, since the cost basis of Berkshire's bank, insurance, and finance stocks after the first quarter was just slightly higher than it was at the end of 2020.\nDuring the Q&A part of Berkshire's shareholder meeting, Buffett was asked why he had sold most of his bank stocks last year.\n\"I like banks generally, I just didn't like the proportion we had compared to the possible risk if we got the bad results that so far we haven't gotten,\" Buffett said. \"We overall didn't want as much in banks as we had.\"\nThe Oracle of Omaha added: \"The banking business is way better than it was in the United States 10 or 15 years ago. The banking business around the world -- in various places -- might worry me. But our banks are in far, far better shape than 10 or 15 years ago. But when things froze for a short period of time, the biggest thing the banks had going for them was that the Federal Reserve was behind them, and the Federal Reserve is not behind Berkshire. It's up to us take care of ourselves.\"\nWhat to make of this\nBuffett is one of the greatest investing minds of all time, if not No. 1, so it's important to realize that it will be difficult for us to see these moves exactly as he does. And I can certainly appreciate his remark about having too much exposure. Keep in mind, Buffett is managing an equities portfolio of hundreds of billions of dollars, so a few percentage points one way or the other is huge. He needs to think about safety much more than your standard responsible investor (Buffett sometimes refers to himself as Berkshire's \"chief risk officer,\" and he did so again on Saturday). But it really is difficult for me to understand all these moves.\nGoldman Sachs is not very loan-heavy, so it didn't really face the same degree of risk as other large banks like Bank of America and JPMorgan Chase. Investment banks also tend to do better in periods of volatility, and Goldman is working to build up its consumerbankand asset and wealth management divisions to generate steadier revenues. Goldman's stock is nearly 40% higher than it was prior to the pandemic, and many thinkit's still trading cheap.\nBuffett's decision to load up on Bank of America and dump JPMorgan as an even bigger mystery to me. JPMorgan not only has a more diversified business, but its earnings power is greater, as well. The bank is also extremely safe. Its reserves for loan losses peaked at $34 billion during 2020, but the bank was prepared for scenarios where its reserves would have peaked at $52 billion. JPMorgan also engineered its way through the Great Recession better than any of the largest banks in America. Buffett officially eliminated Berkshire's stake in JPMorgan in the fourth quarter of the year. Meanwhile, the stock is up nearly 21% year to date at Tuesday's prices, and Buffett likely missed out on even more appreciation, considering he sold the bulk of his JPMorgan position in the third quarter of 2020.\nHindsight is, of course, 20/20, but the numbers are also the numbers, and Buffett missed out on huge gains on his former bank holdings that could just be getting started. Banks are potentially poised for a strong multiyear run, with earnings expected to jump in a rising-rate environment. Buffett did say Saturday that he is concerned about \"very substantial inflation,\" so maybe he thinks too much inflation may kill loan demand, or that rising rates might reveal bad credit quality. However, cyclical stocks like banks and financials tend to perform better during inflation than high-growth tech stocks, which Berkshire has recently made abigger part of its portfoliothan financials.\nIs Buffett done with banking?\nBuffett has not abandoned the sector altogether. Bank of America is still Berkshire's second-largest holding behindApple. Berkshire also still has large positions inAmerican Express, U.S. Bancorp, andBank of New York Mellon. Buffett also may not be pulling all the strings here -- he's ceded a lot of Berkshire's investing authority to others who may be making the decisions. It has long been known that two of Buffett's lieutenants, Todd Combs and Ted Weschler, are much more involved in Berkshire's portfolio decisions now. In addition, Berkshire recently confirmed that Berkshire's Vice Chairman Greg Abel isexpected to succeed Buffettas CEO when he eventually steps aside.\nBut with all that has recently happened, it does seem like it could be a while until we see Berkshire buy traditional bank stocks again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":374,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102104974,"gmtCreate":1620181547798,"gmtModify":1634207166695,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Why not take financial firms?","listText":"Why not take financial firms?","text":"Why not take financial firms?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/102104974","repostId":"2132510217","repostType":4,"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102102519,"gmtCreate":1620181474631,"gmtModify":1634207167435,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Not financial institution?","listText":"Not financial institution?","text":"Not financial institution?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102102519","repostId":"2132510807","repostType":4,"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101760743,"gmtCreate":1619944414382,"gmtModify":1634208935961,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Medical device maker","listText":"Medical device maker","text":"Medical device maker","images":[{"img":"https://static.tigerbbs.com/b8312ff14dba3340f846aecfdb4bf4d5","width":"750","height":"1769"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/101760743","isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":103526597,"gmtCreate":1619794633519,"gmtModify":1634209864283,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103526597","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://www.laohu8.com/m/news/1115363330?lang=&edition=full","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1},"isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103528827,"gmtCreate":1619794546769,"gmtModify":1634209865133,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Good info","listText":"Good info","text":"Good info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/103528827","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://www.laohu8.com/m/news/1115363330?lang=&edition=full","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103521217,"gmtCreate":1619794510939,"gmtModify":1634209865719,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Interesting and bravo","listText":"Interesting and bravo","text":"Interesting and bravo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103521217","repostId":"1144609375","repostType":4,"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370499308,"gmtCreate":1618617692204,"gmtModify":1631884329682,"author":{"id":"3576543142815799","authorId":"3576543142815799","name":"Julyvictor","avatar":"https://static.tigerbbs.com/46bde596fe80bee533460fc78fbc1d3b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576543142815799","authorIdStr":"3576543142815799"},"themes":[],"htmlText":"Is Tesla worth? Hope so","listText":"Is Tesla worth? Hope so","text":"Is Tesla worth? Hope so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/370499308","isVote":1,"tweetType":1,"viewCount":440,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}